All In Biotech

Drug Trial Radar · NCT01564095

TOP-Study (Tacrolimus Organ Perfusion): Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion

TOP-Study (Tacrolimus Organ Perfusion): A Prospective Multicenter Trial for Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion

Last checked: Nov 20, 2026Latest source record: Mar 23, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

25

Actual

Start

Oct 2011

Primary completion

Jul 2013

Study completion Jul 2013

Sponsor

Lead sponsor
Ludwig-Maximilians - University of MunichAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 27, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Utilisation of extended criteria donors due to critical organ shortage contributes to increased ischemia reperfusion injury as well as mortality following liver transplantation. Experimental data show protective effects on hepatic ischemia reperfusion injury (IRI) using the calcineurin inhibitor Tacrolimus applied intravenously or directly as a hepatic rinse. Moreover clinical data indicate a protective role of a Tacrolimus rinse in human liver transplantation when using normal, healthy grafts. The effects of Tacrolimus on hepatic injury in extended donor criteria (EDC) liver grafts remain unclear. Therefore, the aim of the present study is to examine the effects of a Tacrolimus ex vivo rinse (20 ng/ml) on cellular injury after transplantation of marginal liver grafts exhibiting 2 or more EDCs according to Eurotransplant's definition of EDC grafts.

Conditions

  • Terminal Liver Disease
  • Ischemia Reperfusion Injury
  • Graft Dysfunction
  • Graft Failure
  • Poor Graft Quality

Interventions

  • TacrolimusDrug

    Marginal liver grafts are flushed with Tacrolimus (20ng/ml) solved in 1000 ml HTK preservation solution (duration: 15 min) ex vivo at the end of backtable preparation in the experimental group.

  • HTK/PlaceboDrug

    Marginal liver grafts are flushed with 1000 ml HTK preservation solution(duration: 15 min) ex vivo at the end of backtable preparation in the placebo group.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum serum ALT-levelTime frame: 48 hrs following liver transplantation

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Department of General, Visceral and Transplantation Surgery, Charité Campus Virchow-Klinikum

    Berlin, Germany

  • Department of General and Visceral Surgery, Johann Wolfgang Goethe-University

    Frankfurt am Main, Germany

  • Department of General, Visceral and Transplantation Surgery, Ruprecht Karls University

    Heidelberg, Germany

  • Department of Transplantation Surgery, Johannes Gutenberg University

    Mainz, Germany

  • Ludwig-Maximilians University, Campus Grosshadern, Department of Surgery

    Munich, Germany

  • Department of Surgery, University of Regensburg

    Regensburg, Germany

  • Department of General, Visceral and Transplantation Surgery, Eberhard Karls University

    Tübingen, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.